Literature DB >> 28208102

Oncogenic growth factor signaling mediating tumor escape from cellular immunity.

Fernando Concha-Benavente1, Robert L Ferris2.   

Abstract

Unrestrained growth factor signals can promote carcinogenesis, as well as other hallmarks of cancer such as immune evasion. Our understanding of the function and complex regulation of HER family of receptors has led to the development of targeted therapeutic agents that suppress tumor growth. However, these receptors also mediate escape from recognition by the host immune system. We discuss how HER family of oncogenic receptors downregulate tumor antigen presentation and upregulate suppressive membrane-bound or soluble secreted inhibitory molecules that ultimately lead to impaired cellular immunity mediated by cytotoxic T lymphocyte (CTL) recognition. Implementing this knowledge into new therapeutic strategies to enhance tumor immunogenicity may restore effector cell mediated immune clearance of tumors and clinical efficacy of tumor-targeted immunotherapy against HER receptor overexpression.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28208102      PMCID: PMC5449256          DOI: 10.1016/j.coi.2017.01.004

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  59 in total

Review 1.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

Review 2.  Signal transduction and oncogenesis by ErbB/HER receptors.

Authors:  Mina D Marmor; Kochupurakkal Bose Skaria; Yosef Yarden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

Review 3.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.

Authors:  Esra A Akbay; Shohei Koyama; Julian Carretero; Abigail Altabef; Jeremy H Tchaicha; Camilla L Christensen; Oliver R Mikse; Andrew D Cherniack; Ellen M Beauchamp; Trevor J Pugh; Matthew D Wilkerson; Peter E Fecci; Mohit Butaney; Jacob B Reibel; Margaret Soucheray; Travis J Cohoon; Pasi A Janne; Matthew Meyerson; D Neil Hayes; Geoffrey I Shapiro; Takeshi Shimamura; Lynette M Sholl; Scott J Rodig; Gordon J Freeman; Peter S Hammerman; Glenn Dranoff; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-09-27       Impact factor: 39.397

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Authors:  Michael S Leibowitz; Raghvendra M Srivastava; Pedro A Andrade Filho; Ann Marie Egloff; Lin Wang; Raja R Seethala; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2013-01-30       Impact factor: 12.531

Review 7.  The two sides of HER2/neu: immune escape versus surveillance.

Authors:  Barbara Seliger; Rolf Kiessling
Journal:  Trends Mol Med       Date:  2013-09-12       Impact factor: 11.951

8.  EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3.

Authors:  Fernando Concha-Benavente; Raghvendra M Srivastava; Soldano Ferrone; Robert L Ferris
Journal:  Oncoimmunology       Date:  2013-12-05       Impact factor: 8.110

9.  Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression.

Authors:  Masayuki Inoue; Kousaku Mimura; Shinichiro Izawa; Kensuke Shiraishi; Ayako Inoue; Shugo Shiba; Mitsuaki Watanabe; Takanori Maruyama; Yoshihiko Kawaguchi; Shingo Inoue; Tomonori Kawasaki; Aniruddha Choudhury; Ryohei Katoh; Hideki Fujii; Rolf Kiessling; Koji Kono
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

10.  Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells.

Authors:  Bishu Sapkota; Charles E Hill; Brian P Pollack
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

View more
  5 in total

1.  A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.

Authors:  Conor E Steuer; Christopher C Griffith; Sreenivas Nannapaneni; Mihir R Patel; Yuan Liu; Kelly R Magliocca; Mark W El-Deiry; Cynthia Cohen; Taofeek K Owonikoko; Dong M Shin; Zhuo G Chen; Nabil F Saba
Journal:  Mol Cancer Ther       Date:  2018-02-13       Impact factor: 6.261

Review 2.  Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance.

Authors:  Nabil F Saba; Zhuo Gerogia Chen; Missak Haigentz; Paolo Bossi; Alessandra Rinaldo; Juan P Rodrigo; Antti A Mäkitie; Robert P Takes; Primoz Strojan; Jan B Vermorken; Alfio Ferlito
Journal:  Mol Cancer Ther       Date:  2019-11       Impact factor: 6.261

3.  Immunological and classical subtypes of oral premalignant lesions.

Authors:  Jean-Philippe Foy; Chloé Bertolus; Sandra Ortiz-Cuaran; Marie-Alexandra Albaret; William N Williams; Wenhua Lang; Solène Destandau; Geneviève De Souza; Emilie Sohier; Janice Kielbassa; Emilie Thomas; Sophie Deneuve; Patrick Goudot; Alain Puisieux; Alain Viari; Li Mao; Christophe Caux; S M Lippman; P Saintigny
Journal:  Oncoimmunology       Date:  2018-09-21       Impact factor: 7.723

4.  KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.

Authors:  Marika Cinausero; Noemi Laprovitera; Giovanna De Maglio; Lorenzo Gerratana; Mattia Riefolo; Marianna Macerelli; Michelangelo Fiorentino; Elisa Porcellini; Vanessa Buoro; Francesco Gelsomino; Anna Squadrilli; Gianpiero Fasola; Massimo Negrini; Marcello Tiseo; Manuela Ferracin; Andrea Ardizzoni
Journal:  Ther Adv Med Oncol       Date:  2019-11-14       Impact factor: 8.168

5.  TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis.

Authors:  Lele Zhu; Yanchuan Li; Xiaoping Xie; Xiaofei Zhou; Meidi Gu; Zuliang Jie; Chun-Jung Ko; Tianxiao Gao; Blanca E Hernandez; Xuhong Cheng; Shao-Cong Sun
Journal:  Nat Cell Biol       Date:  2019-12-02       Impact factor: 28.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.